Dainippon Sumitomo Pharma Co., Ltd. headquartered in Osaka, Japan,
was formed in 2005 through the merger of Dainippon Pharmaceutical
Co., Ltd. and Sumitomo Pharmaceuticals Co., Ltd. The company has
since then concentrated on integrating and solidifying its business
infrastructure by strengthening its national sales network in Japan.
In addition to this major business strategy, DSP has been extending
its research and development capabilities for globally successful
products. DSP is currently developing several compounds through its
local subsidiaries in Europe and the United States. Major products
available in the United States are zonisamide and meropenem, which
were discovered by DSP's research laboratories and are respectively
marketed under license, by Eisai and AstraZeneca.